The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018

被引：1

作者：

Ascierto, Paolo A. ^{[1
]}

Bruzzi, Paolo ^{[2
]}

Eggermont, Alexander ^{[4
]}

Hamid, Omid ^{[5
]}

Tawbi, Hussein A. ^{[7
]}

van Akkooi, Alexander ^{[9
]}

Testori, Alessandro ^{[8
]}

Caraco, Corrado ^{[3
]}

Puzanov, Igor ^{[6
]}

Perrone, Francesco ^{[10
]}

机构：

[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Via Mariano Semmola, I-80131 Naples, Italy

[2] Univ Hosp San Martino, Clin Epidemiol Unit, Genoa, Italy

[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Melanoma Soft Tissue Muscle Skeletal & Head, Naples, Italy

[4] Inst Gustave Roussy Villejuif, Paris Sud, Paris, France

[5] Angeles Clin & Res Inst, Clin Res & Immunotherapy, Los Angeles, CA USA

[6] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA

[7] UT MD Anderson Canc Ctr, Invest Canc Therapeut, Melanoma Med Oncol, Melanoma Clin Res & Early Drug Dev, Houston, TX USA

[8] EORTC Melanoma Grp, Surg Grp, Brussels, Belgium

[9] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Dept Surg Oncol, Amsterdam, Netherlands

[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Clin Trials Unit, Naples, Italy

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2019年 / 17卷

关键词：

Melanoma; Immunotherapy; Anti-PD-1; Anti-CTLA-4; Targeted therapy; BRAF inhibitor; MEK inhibitor; Adjuvant; Neoadjuvant; METASTATIC MELANOMA; STAGE-III; IPILIMUMAB; NIVOLUMAB; SURVIVAL; MULTICENTER; PROGRESSION; THERAPIES;

D O I：

10.1186/s12967-019-1892-5

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

引用

页数：11

共 38 条

[1] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J].

Amaria, Rodabe N. ;

Reddy, Sangeetha M. ;

Tawbi, Hussein A. ;

Davies, Michael A. ;

Ross, Merrick, I ;

Glitza, Isabella C. ;

Cormier, Janice N. ;

Lewis, Carol ;

Hwu, Wen-Jen ;

Hanna, Ehab ;

Diab, Adi ;

Wong, Michael K. ;

Royal, Richard ;

Gross, Neil ;

Weber, Randal ;

Lai, Stephen Y. ;

Ehlers, Richard ;

Blando, Jorge ;

Milton, Denai R. ;

Woodman, Scott ;

Kageyama, Robin ;

Wells, Daniel K. ;

Hwu, Patrick ;

Patel, Sapna P. ;

Lucci, Anthony ;

Hessel, Amy ;

Lee, Jeffrey E. ;

Gershenwald, Jeffrey ;

Simpson, Lauren ;

Burton, Elizabeth M. ;

Posada, Liberty ;

Haydu, Lauren ;

Wang, Linghua ;

Zhang, Shaojun ;

Lazar, Alexanderj ;

Hudgens, Courtney W. ;

Gopalakrishnan, Vancheswaran ;

Reuben, Alexandre ;

Andrews, Miles C. ;

Spencer, Christine N. ;

Prieto, Victor ;

Sharma, Padmanee ;

Allison, James ;

Tetzlaff, Michael T. ;

Wargo, Jennifer A. .

NATURE MEDICINE, 2018, 24 (11) :1649-+

[2] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[3] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[4] Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma [J].

Blank, Christian U. ;

Rozeman, Elisa A. ;

Fanchi, Lorenzo F. ;

Sikorska, Karolina ;

van de Wiel, Bart ;

Kvistborg, Pia ;

Krijgsman, Oscar ;

van den Braber, Marlous ;

Philips, Daisy ;

Broeks, Annegien ;

van Thienen, Johannes, V ;

Mallo, Henk A. ;

Adriaansz, Sandra ;

ter Meulens, Sylvia ;

Pronk, Loes M. ;

Grijpink-Ongering, Lindsay G. ;

Bruining, Annemarie ;

Gittelman, Rachel M. ;

Warren, Sarah ;

van Tinteren, Harm ;

Peeper, Daniel S. ;

Haanen, John B. A. G. ;

van Akkooi, Alexander C. J. ;

Schumacher, Ton N. .

NATURE MEDICINE, 2018, 24 (11) :1655-+

[5]

Blank CU, 2018, ANN ONCOL S8, V29, pLBA42

[6] Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses [J].

Blumenthal, Gideon M. ;

Karuri, Stella W. ;

Zhang, Hui ;

Zhang, Lijun ;

Khozin, Sean ;

Kazandjian, Dickran ;

Tang, Shenghui ;

Sridhara, Rajeshwari ;

Keegan, Patricia ;

Pazdur, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :1008-+

[7]

Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[8] KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. [J].

Carlino, Matteo S. ;

Atkinson, Victoria ;

Cebon, Jonathan S. ;

Jameson, Michael B. ;

Fitzharris, Bernie M. ;

McNeil, Catriona M. ;

Hill, Andrew G. ;

Ribas, Antoni ;

Atkins, Michael B. ;

Thompson, John A. ;

Hwu, Wen-Jen ;

Hodi, F. Stephen ;

Menzies, Alexander M. ;

Guminski, Alexander David ;

Kefford, Richard ;

Shu, Xinxin ;

Ibrahim, Nageatte ;

Moreno, Blanca Hornet ;

Long, Georgina V. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[9] Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study [J].

Ciani, Oriana ;

Buyse, Marc ;

Garside, Ruth ;

Pavey, Toby ;

Stein, Ken ;

Sterne, Jonathan A. C. ;

Taylor, Rod S. .

BMJ-BRITISH MEDICAL JOURNAL, 2013, 346

[10] A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma [J].

Diab, Adi ;

Rahimian, Shah ;

Haymaker, Cara L. ;

Bernatchez, Chantale ;

Andtbacka, Robert Hans Ingemar ;

James, Marihella ;

Johnson, Douglas Buckner ;

Markowitz, Joseph ;

Murthy, Ravi ;

Puzanov, Igor ;

Shaheen, Montaser F. ;

Swann, Suzanne .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 →